Claris raises $57M in Series A as it awaits key trial readout on eye drug
Summary
Claris an\xadnounced a $57 mil\xadlion Se\xadries A on Thurs\xadday morn\xading as it launched from stealth. The Jer\xadsey City biotech is work\xading on an eye drug based on in\xadves\xadti\xadga\xadtions by Har\xadvard re\xadsearchers.The treat\xadment is a so\xadlu\xadtion of re\xadcom\xadbi\xadnant hu\xadman vari\xadant he\xadpa\xadto\xadcyte growth fac\xadtor, or dHGF, which Claris be\xadlieves can ac\xadcel\xader\xadate and im\xadprove heal\xading of the cornea, the out\xader\xadmost clear tis\xadsue cov\xader\xading the front of the eye.Unlock this article instantly by becoming a free subscriber. Youll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.